Genentech’s Polivy Gets US FDA Panel Nod For First-Line Use In Large B-Cell Lymphoma

Advisory committee members were swayed by a progression-free survival benefit, and the reduction in salvage therapies, with a polatuzumab-containing regimen relative to the highly effective standard of care in the POLARIX trial.

Thumbs up
An expanded indication for Polivy got a thumbs-up from ODAC. • Source: Shutterstock

Genentech, Inc.’s antibody drug conjugate Polivy (polatuzumab vedotin-piiq) has a favorable benefit-risk profile for front-line treatment of diffuse large B-cell lymphoma and should be considered an option, but not necessarily a replacement, for the current highly effective standard of care, US Food and Drug Administration advisory committee members said on 9 March.

Eleven of 13 members of the Oncologic Drugs Advisory Committee looked favorably upon the results from POLARIX, a Phase III...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA Performance Tracker

More from Regulatory Trackers